Delagil is an amebicidal and antimalarial drug, an immunosuppressant.
Release form and composition
Delagil tablets are white, flat, with a beveled edge, odorless. 1 tablet contains the active substance - chloroquine - in the amount of 250 mg.
Auxiliary substances of the drug are: colloidal hydrophobic silicon dioxide, magnesium stearate, corn starch, talc, polyacrylic acid, polyvinyl butyral.
Delagil is sold in blisters of 10 pcs.
Indications for use
According to the instructions, Delagil is indicated for use in the following cases:
- Rheumatoid arthritis;
- Systemic lupus erythematosus in acute and subacute form;
- Prevention and treatment of malaria;
- Extraintestinal amebiasis;
- Rheumatoid arthritis.
According to the instructions, Delagil is contraindicated for use with:
- Severe heart rhythm disorders;
- Oppression of bone marrow hematopoiesis;
- Hepatic and / or renal failure;
- Hypersensitivity to the active or auxiliary components of the drug;
- Pregnancy and breastfeeding;
- Psoriatic arthritis;
With caution appoint delagil for epilepsy, retinopathy, deficiency of glucose-6-phosphate dehydrogenase.
Dosing and Administration
For the prevention of malaria, delagil is prescribed as follows:
- During the first week, 2 tablets of the medication are taken twice;
- The second and all subsequent weeks Delagil is taken once a week (preferably on the same day at about the same time).
For the treatment of malaria, 1000 mg (4 tablets) of Delagil are taken on the first day, and another 500 mg (2 tablets) are taken in 6-8 hours. On the second day, take 750 mg (3 tablets) at a time, on the third day the treatment regimen is the same as in the second.
For amebiasis, delagil is taken three times a day according to the following scheme:
- In the first week, the dose is 500 mg (2 tablets) per day;
- In the second week - 250 mg (1 tablet) per day.
For the next 2-6 months, delagil is taken 750 mg (3 tablets) twice a week.
For rheumatoid arthritis, 500 mg of medication is prescribed (2 tablets):
- In the first week - twice a day;
- Throughout the year - once a day.
With systemic lupus erythematosus, the drug is indicated daily in 250-500 mg (1-2 tablets). With photodermatosis, the dose of Delagil is 250 mg (1 tablet) for one week, after which it is increased to 500-750 mg (2-3 tablets) per day. The duration of therapy is three days.
For children, the drug on the first day is prescribed in the following doses:
- Up to a year –50 mg (0.25 tablets);
- 1-6 years - 125 mg (0.5 tablets);
- 6-10 years - 250 mg (1 tablet);
- 10-15 years - 500 mg (2 tablets).
On the second and third day, the dose of Delagil for children is halved.
The use of Delagil may cause the development of the following side effects:
- Central and peripheral nervous systems: dizziness, convulsions, headache, neuropathy, psychomotor agitation, psychosis, sleep disorders;
- Sense organs: hearing loss, tinnitus, corneal clouding, accommodation disturbances, blurred vision, retinopathy, reversible keratopathy, temporal or annular scotoma;
- Musculoskeletal system: myopathy;
- Cardiovascular system: lowering blood pressure, cardiomyopathy with changes on the electrocardiogram (especially when taking the drug in high dosages);
- Blood system: thrombocytopenia, leukopenia;
- Digestive system: nausea and vomiting, anorexia, diarrhea, abdominal cramps, weight loss, liver damage (when used in high doses);
- Skin reactions: photosensitivity, dermatitis, gray hair, baldness, rash, itching, skin and mucous membrane pigmentation disorders. When dermatitis occurs, the dose of Delagil is reduced or canceled.
Combined use of Delagil with gold preparations, levamisole, penicillamine, phenylbutazone, cytotoxic drugs increases the risk of skin lesions and bone marrow aplasia.
Antacids violate the absorbability of the active substance Delagil, and cimetidine increases its concentration in the blood. Combination of the drug with other antimalarial drugs can cause antagonistic action.
Delagil combination with:
- Glucocorticosteroids - increases the likelihood of cardiomyopathy and myopathy;
- MAO inhibitors - increases the likelihood of developing neurotoxicity;
- Cardiac glycosides - the development of glycosidic intoxication is likely;
- Ethanol - can develop hepatotoxicity.
In case of an overdose of delagil, the following symptoms may occur:
- Visual impairment;
- Impairment of consciousness;
- Depression of the respiratory center;
If the patient does not receive medical care in time (within 2 hours from the moment of respiratory depression), death is possible as a result of an overdose. It is necessary to wash the stomach of the patient, induce vomiting, ensure the admission of adsorbents, conduct plasmapheresis, peritoneal dialysis.
During delagil therapy, the patient should regularly perform general blood tests and check his eyesight.
Since delagilom therapy can cause a decrease in the clarity of visual perception, patients are advised to use caution when managing potentially dangerous mechanisms that require increased concentration of attention.
Structural analogues of Delagil are Chloroquine, Chloroquine phosphate and Hingamin.
Terms and conditions of storage
According to the instructions, delagil is stored in a cool place out of reach of moisture and direct sunlight. The drug should be protected from children!
The shelf life of the drug is 5 years.